Illumina Applies CE Mark to MiSeqDx™ Cystic Fibrosis System: Omixon Target is Featured!

09/07/2013

We have amazing news today as the first CE mark for next generation sequencing-based molecular diagnostics was just announced. Illumina applied CE mark to MiSeqDx™ Cystic Fibrosis System and Omixon Target is used for analyzing CFTR gene in prenatal labs! An excerpt from the announcement relevant to Omixon Target: Cystic fibrosis...

Omixon on LinkedIn!

23/06/2013

We see amazing potential in using social media channels for spreading the word about next generation sequencing, HLA typing and bioinformatics in general. This is why we have been writing this blog, updating the Facebook and Twitter channels and now we open a new channel on LinkedIn. We hope to...

Flashcard Fridays – Comparison of variant callers

21/06/2013

A survey of tools for variant analysis of next-generation genome sequencing data. Pabinger et al. 2013 Following last week”s variant caller themed FF post, I will present you a very great article about variant detection and annotation. The paper gives a great review of basically every aspect of NGS based...

The Omixon App in Illumina’s genomics cloud computing and storage platform

19/05/2013

It’s a huge pleasure to announce that BaseSpace, Illumina’s genomics cloud computing and storage platform, just became commercially available and one of the first apps was launched by Omixon. The commercial release includes a fully supported BaseSpace Apps store for quick and easy access to Illumina and third-party bioinformatics applications.

Webinar about HLA typing from NGS data

17/05/2013

Broadcast date: 29 May 2013, Wednesday Time: 9.00-10.00 AM PT/ 18.00-19.00 CET Come and join our CEO, Attila Berces online in a presentation and demo of how Omixon Target HLA typing will bring you value during the analysis of NGS data. Register today! Currently, there are 69 on-going clinical trials...